The World's Leading Source for FDA Broadcasting

About FDALive

FDALive.com Internet Privacy Statement


Protecting your privacy is important to us. We hope the following statement will help you understand how FDALive.com collects, uses and safeguards the personal information you provide to us on our site.

When visitors access the FDALive.com Web site, they are free to browse anonymously. We do not track visitors e-mail, pages browsed, etc. When you register for the FDALive.com on-line service, you can be assured that your privacy is safeguarded on our secure site. We have implemented the use of Secure Socket Layer (SSL) technology to provide the highest level of Internet security available today. The SSL protocol encrypts your personal information being transferred over the Internet.

Personal Information:

To register for the FDALive.com on-line services, personal data will be requested for the sole purpose of setting up an account. This information will include name, company name, address, e-mail, telephone number and payment information. This information will be used to provide the FDALive.com services, for billing purposes, to correspond with you about your order and to inform you of new FDALive.com services.

FDALive.com guarantees that we will not sell your personal information to any other entities.

Declining E-Mail Offers:

We understand that some of our members may prefer to not receive e-mail announcements from FDALive.com regarding new or enhanced services. To request that your e-mail information be removed from any FDALive.com marketing activities, simply access your FDALive account and Select the "Edit Account" option. Near the bottom of the screen, opt-out of future e-mails by de-selecting the checkbox and then "Update" your membership.

Inquiries Regarding FDALive.com's Privacy Policy:

Please direct any questions you may have regarding our policies to support@FDALive.com.

Upcoming Meetings

Recent Meetings

Meeting OptionsMeeting OptionsMeeting OptionsOncologic Drugs AdComm

Meeting Date: 7/9/15-7/9/15

Meeting Details:

The committee will discuss biologics license application 125547, necitumumab injection, application submitted by Eli Lilly and Company. The proposed indication (use) for this product is in combination with gemcitabine and cisplatin for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer.


Location: FDA Meeting Room Related News Links: Not Available
Time: 8:00AM-5:00PM    

View Meeting Details / News

Past Meetings

Below is a listing of all committees. Select a committee to display all meetings available for that committee.

Live Meetings